抽象的な
Challenges of combining cytotoxic chemotherapy and tyrosine kinase inhibitors
Michael P Chu, Vijaya L Damaraju & Michael B SawyerSingle-agent tyrosine kinase inhibitors (TKIs) have significantly improved patient outcomes across multiple tumor subtypes. However, TKI therapy is rarely curative. Early optimism of combining TKIs with cytotoxic chemotherapy failed to produce substantial results in numerous randomized studies. This article highlights potential missteps and improvements in combination therapy thus far, while shedding light on potential improvements for future combinations.
免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません